Počet záznamů: 1
The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology
- 1.
SYSNO ASEP 0504220 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název The impact of anorexigenic peptides in experimental models of Alzheimer's disease pathology Tvůrce(i) Maletínská, L. (CZ)
Popelová, A. (CZ)
Železná, B. (CZ)
Bencze, Michal (FGU-C) RID, ORCID, SAI
Kuneš, Jaroslav (FGU-C) RID, ORCIDZdroj.dok. Journal of Endocrinology. - : BioScientifica - ISSN 0022-0795
Roč. 240, č. 2 (2019), R47-R72Poč.str. 26 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova Alzheimer's disease pathology ; experimental rodent models ; leptin ; anorexigenic neuropeptides Vědní obor RIV ED - Fyziologie Obor OECD Neurosciences (including psychophysiology Způsob publikování Open access Institucionální podpora FGU-C - RVO:67985823 UT WOS 000457095300001 EID SCOPUS 85061809603 DOI 10.1530/JOE-18-0532 Anotace Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the elderly population. Numerous epidemiological and experimental studies have demonstrated that patients who suffer from obesity or type 2 diabetes mellitus have a higher risk of cognitive dysfunction and AD. Several recent studies demonstrated that food intake lowering (anorexigenic) peptides have the potential to improve metabolic disorders and that they may also potentially be useful in the treatment of neurodegenerative diseases. In this review, the neuroprotective effects of anorexigenic peptides of both peripheral and central origins are discussed. Moreover, the role of leptin as a key modulator of energy homeostasis is discussed in relation to its interaction with anorexigenic peptides and their analogs in AD-like pathology. Although there is no perfect experimental model of human AD pathology, animal studies have already proven that anorexigenic peptides exhibit neuroprotective properties. This phenomenon is extremely important for the potential development of new drugs in view of the aging of the human population and of the significantly increasing incidence of AD. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2020 Elektronická adresa https://joe.bioscientifica.com/downloadpdf/journals/joe/240/2/JOE-18-0532.pdf
Počet záznamů: 1